Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.61 |
| ▸ | TUBB | P07437 | 1/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.61 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.61 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.61 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.61 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.61 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.61 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.61 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.61 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.61 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.61 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921550 | 0.89 | RAB9A (0.69) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL13044031 | 0.85 | MEN1 (0.64) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL13043504 | 0.82 | MEN1 (0.60) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL16384112 | 0.82 | MEN1 (0.60) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL13043491 | 0.81 | RAB9A (0.54) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL13044050 | 0.81 | MEN1 (0.54) | RAB9AKMT2ANPC1MEN1TUBB4A | |
| SCHEMBL13044434 | 0.81 | KMT2A (0.59) | RAB9AKMT2ANPC1MEN1ALDH1A1 | |
| SCHEMBL15908288 | 0.81 | TUBB4A (0.82) | RAB9AKMT2ANPC1MEN1TUBB4A | |
| SCHEMBL3166384 | 0.79 | TUBB4A (0.85) | KMT2AMEN1TUBB4ATUBBTUBA3C | |
| SCHEMBL23625291 | 0.78 | TUBB4A (0.82) | RAB9AKMT2ANPC1MEN1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | claimed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-7579365-B2 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ZIOPHRAM ONCOLOGY, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2008-01-31 | — | — | US | disclosed |
| US-20030023093-A1 | United states patent office | ASTA MEDICA AKTIENGESELLSCHAFT | 2003-01-30 | — | — | US | disclosed |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ZIOPHARM ONCOLOGY, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6232327-B1 | AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | disclosed |
| US-6008231-A | ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS | ASTA MEDICA AKTIENGESELLSCHGT (DE) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023093-A1 | United states patent office | IDO1, IDO2, TDO2 | RAB9A 4591/4885KMT2A 3506/4885NPC1 2176/4885 |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | RAB9A 4612/4885KMT2A 3037/4885NPC1 2538/4885 |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | RAB9A 3511/4885KMT2A 1157/4885NPC1 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.